The debate about pharmacogenomics (PGx) as a future tool in healthcare divides the clinical research community today. Some researchers doubt the benefit while others see huge potential.

In fact, the research evidence shows that the real question is how PGx should be deployed, not if, as a white paper by Bruce Quinn Associates indicates.

(*Indicates a mandatory field)

First name*

Last name*

Institution*

Telephone*

City*

Country/Region*

Please selectAngolaAustriaBelgiumBotswanaCanadaCzech RepublicDenmarkFinlandFranceGermanyGibraltarGuernseyHungaryItalyJerseyLesothoLiechtensteinLuxembourgMalawiMonacoMozambiqueNamibiaNetherlandsNorwayPolandPortugalSlovakiaSouth AfricaSpainSwedenSwitzerlandUnited KingdomUnited StatesZambiaZimbabwe

Email*

Download the white paper